The BioNTech SE ADR BNTX rose 4.79% to $118.47 Tuesday, on what proved to be an all-around great trading session for the ...

The BioNTech SE ADR BNTX inched 0.69% higher to $113.05 Monday, on what proved to be an all-around positive trading session ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on BioNTech SE (BNTX – Research Report), with a ...

BioNTech stock has climbed 26% over four days as the German biotech rides a round of cancer treatment success from Summit Therapeutics. A rival posted encouraging data on a drug that outperformed ...

BioNTech has been boosted a wave of enthusiasm over another company’s cancer drug, which has turned the biopharma industry ...

Ford is one of the many stocks on this list of the best dividend stocks in the S&P 500 that have seen shares slump lately.

Today, Benzinga 's options scanner spotted 26 uncommon options trades for BioNTech. This isn't normal. The overall sentiment ...

BioNTech (BNTX) stock traded higher on Tuesday after Jefferies upgraded the COVID-19 vaccine maker to Buy, citing the ...

Summit Therapeutics acquired rights to ivonescimab outside of China and Australia. With Keytruda sales up around $25 billion ...

The company's best days as a top pandemic vaccine supplier might be over, but it still has enough potential to be compelling.

H.C. Wainwright analyst Robert Burns has reiterated their bullish stance on BNTX stock, giving a Buy rating on September 9. Robert Burns has ...

We recently compiled a list of the 10 Worst Cancer Stocks To Buy Now According to Short Sellers. In this article, we are ...